Despite these limitations, this study provides a foundation for future efforts to exploit ESRP1 reactivation therapeutically and offers a specialized tool to accelerate the discovery of novel DNMT inhibitors for RCC. The gene discussed is ESRP1; the disease is renal cell carcinoma.